A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies

…, GS Dizerega, MJ Baltezor, J Espinosa… - Cancer chemotherapy …, 2015 - Springer
Purpose This multicenter, open-label, dose-escalating, phase I study evaluated the safety,
tolerability, pharmacokinetics and preliminary tumor response of a nanoparticulate …

Tyr1-ψ[(Z)CF═CH]-Gly2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin

…, LG Rajewski, PC Toren, MJ Baltezor… - ACS chemical …, 2018 - ACS Publications
Opioid peptides are key regulators in cellular and intercellular physiological responses, and
could be therapeutically useful for modulating several pathological conditions. Unfortunately…

Preclinical pharmacokinetics of fosciclopirox, a novel treatment of urothelial cancers, in rats and dogs

…, M Dalton, GA Reed, RA Jensen, MJ Baltezor… - … of Pharmacology and …, 2019 - ASPET
Pharmacokinetic studies in rats and dogs were performed to characterize the in vivo
performance of a novel prodrug, fosciclopirox. Ciclopirox olamine (CPX-O) is a marketed topical …

[HTML][HTML] Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex

…, W McCulloch, M Dalton, GA Reed, MJ Baltezor… - Cell Death & …, 2021 - nature.com
Ciclopirox (CPX) is an FDA-approved topical antifungal agent that has demonstrated preclinical
anticancer activity in a number of solid and hematologic malignancies. Its clinical utility …

[HTML][HTML] Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression …

…, HA Maulhardt, SJ Verco, AM Marin, MJ Baltezor… - Oncology and …, 2024 - Springer
This review summarizes development of large surface area microparticle paclitaxel (LSAM-PTX)
and docetaxel (LSAM-DTX) for local treatment of primary carcinomas with emphasis on …

Pharmacokinetics of ciclopirox prodrug, a novel agent for the treatment of bladder cancer, in animals and humans.

SJ Weir, R Wood, MJ Baltezor, G Reed, AE Brinker… - 2019 - ascopubs.org
e14705 Background: Ciclopirox Prodrug (CPX-POM) is a novel anticancer agent currently
being evaluated in patients with advanced solid tumors participating in a First-in-Human, …

Preclinical development of ciclopirox prodrug for the treatment of non-muscle invasive and muscle invasive bladder cancer.

…, G Reed, AE Brinker, W McCulloch, MJ Baltezor… - 2018 - ascopubs.org
e14576 Background: Ciclopirox (CPX) is an antifungal agent contained in a number of FDA-approved
topical drug products. CPX possesses anticancer activity in a number of in vitro …

[PDF][PDF] Bench-to-bedside translation of ciclopirox prodrug for the treatment of non-muscle invasive and muscle-invasive bladder cancer

…, W McCulloch, GA Reed, A Brinker, MJ Baltezor… - Can Res, 2018 - ciclomed.com
Background & Significance Acknowledgements In Vitro Proof of Principle In Vivo Proof of
Principle Ongoing and Future Studies Page 1 1University of Kansas Medical Center, Kansas …

Safety, dose tolerance, pharmacokinetics and pharmacodynamics study of CPX-POM in patients with advanced solid tumors.

…, R Challenger, P Ramamoorthy, G Reed, MJ Baltezor… - 2018 - ascopubs.org
TPS2618 Background: Ciclopirox (CPX) is an antifungal agent contained in a number of
FDA-approved topical drug products. CPX possesses anticancer activity in a number of in vitro …

[BOOK][B] PREPARATION AND EVALUATION OF BIS-(3-CARBOXY-4-HYDROXY-1-NAPHTHYL) ALKANONES AS NOVEL COMPLEXING AGENTS. COMPLEXATION …

MJ Baltezor - 1976 - search.proquest.com
Complexation or molecular association may be defined as a weak, reversible interaction
between organic molecules. For this study, this interaction may be further classified as that …